“Growing Antibiotic Resistance and the Demand for Novel Drugs”
A key trend driving the infectious diseases small molecule API market is the escalating issue of antimicrobial resistance (AMR), which has created an urgent need for novel, effective antibiotics. As bacteria develop resistance to current treatments, there is a growing demand for new small molecules capable of targeting these resistant strains. Governments and global health organizations are actively supporting research into new antibiotics, with initiatives such as the Antimicrobial Resistance Innovation Fund promoting investment in AMR-focused drug development. For instance, the introduction of new antibiotic classes like ceftolozane-tazobactam and meropenem-vaborbactam is specifically aimed at combating multi-drug-resistant bacterial infections.
